Latest news with #ABT
Daily Record
12 hours ago
- Sport
- Daily Record
Crack shots at Dalbeattie Civic Gun Club competition
Twenty-six Dalbeattie Civic Gun Club competitors took part in the new shoot at Little Cloak Farm, Dalbeattie on Saturday. The competition was the Andy McLeod Memorial Shoot and Andy's widow Mary generously presented a new trophy for the competition in his memory. The 25 bird DTL event was won by Brian Renwick on 72x75 after a shoot off with Ian Edmonds on the same score. To add a little bit of fun to this event, a single white clay was added to the mix for each squad on a random basis. Only three competitors managed to hit their white target – Stevie Allan, Colin Clark and Clem Proudlock – and after a shoot-off Clem was declared the winner. Event two was shot over 25 ABT targets with Stevie Allan emerging as winner on a perfect 25. Event three consisted of 10 pair of doubles and this was won by Finley Bell on an excellent 19x20. There was also a pool trap competition ongoing during the day and this was won by Finley Bell on a perfect eight. The total scores for all three events were added together and the highest scorer and overall winner was Stevie Allan and he received the Andy McLeod Memorial Trophy. Other principal prizewinners were: Event 1 – 72 pts: Brian Renwick, I Edmonds. 71 pts: S Allan, A Peacock. 70 pts: D Galloway, B Renwick. 68 pts: S Nichol, W Little. Event 2 – 25 pts: S Allan. 24 pts: G Fleming, F Bell, C Maxwell. 23 pts: A Peacock, I Edmonds. Event 3 – 19 pts: F Bell. 18 pts: S Allan. 17 pts: A Peacock, B Renwick. 16 pts: G Fleming, D McCulloch.
Yahoo
3 days ago
- Business
- Yahoo
What to Expect From Abbott Laboratories' Q2 2025 Earnings Report
With a market cap of $233.8 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, manufactures, and sells a diverse range of healthcare products across diagnostics, medical devices, nutritionals, and branded generics in emerging markets. Abbott has grown through strategic acquisitions, such as St. Jude Medical and Alere Inc., while streamlining its portfolio through divestitures, including its developed markets generics and vision care businesses. The North Chicago, Illinois-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Thursday, July 17. Ahead of the event, analysts are expecting ABT to report an adjusted EPS of $1.25, up 9.7% from $1.14 in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, Abbott exceeded the consensus adjusted EPS estimate by 1.9%. Holiday Trading, Trade Negotiations and Other Key Things to Watch this Week Alphabet's Strong Free Cash Flow Makes GOOG Stock a Value Buy Alibaba Is Restructuring Its E-Commerce Unit. How Should You Play BABA Stock Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, analysts expect the medical device maker to report adjusted EPS of $5.16, up 10.5% from $4.67 in fiscal 2024. Looking forward to fiscal 2026, adjusted EPS is expected to grow 9.9% year-over-year to $5.67. Shares of ABT have surged 28.4% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 12.6% rise and the Health Care Select Sector SPDR Fund's (XLV) 8.2% decline over the same period. Despite reporting weaker-than-expected Q1 2025 revenue of $10.4 billion, shares of Abbott Laboratories rose 2.8% on Apr. 16. The company reaffirmed its full-year 2025 profit forecast of $5.05 per share to $5.25 per share. Abbott also announced $500 million in new investments in manufacturing and R&D in Illinois and Texas, which are expected to mitigate the impact of U.S. tariffs estimated at around $300 million. Additionally, stronger-than-expected Q1 adjusted EPS of $1.09, along with ongoing global production of high-demand products like the FreeStyle Libre, boosted investor sentiment. Analysts' consensus rating on Abbott stock is bullish, with a "Strong Buy" rating overall. Among 26 analysts covering the stock, 18 recommend a "Strong Buy,' two have a "Moderate Buy" rating, and six give a "Hold" rating. This configuration is slightly more bullish than three months ago, with 17 analysts suggesting a "Strong Buy." The average analyst price target for ABT is $143.65, indicating a potential upside of just 6.9% from the current levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
25-06-2025
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
25-06-2025
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
South China Morning Post
22-06-2025
- Entertainment
- South China Morning Post
Pioneering ballet dancer Misty Copeland on diversity and what's next for her
Ten years ago this month, Misty Copeland sat in front of a hastily arranged news conference fighting back tears of pride over her new role: principal dancer for New York's American Ballet Theatre (ABT) company. 'This is it,' she said, with emotion. 'This has been my dream since I was 13.' The occasion was highly unusual. Normally, when a dancer is promoted, a brief press release is issued. But this was Copeland, a crossover star with fame beyond the insular world of ballet. And now she was becoming the first black female principal in the company's history – just days after her New York debut as the lead in Swan Lake brought a refreshingly diverse, packed audience to the Metropolitan Opera House. Now, a decade and many accomplishments later, Copeland is retiring from the company she joined as a teenager. 'It's been 25 years at ABT, and I think it's time,' said Copeland, 42, last week. 'It's time for me to move to the next stage.' Misty Copeland, who spent 25 years at American Ballet Theatre, is retiring from the company. Photo: Taylor Jewell/Invision/AP The company is planning a splashy farewell on October 22, featuring performances by Copeland at New York's Lincoln Centre – for the first time in five years – and other dancers. There will be speeches and film clips.
